Seventh Circuit sets September 24 arguments in Lilly's retatrutide classification appeal
A federal appeals court will hear argument September 24 on how retatrutide is classified, which sets its US market exclusivity at twelve years or five.
The Seventh Circuit has scheduled oral argument for September 24, 2026 in Eli Lilly's appeal over how US regulators classify retatrutide, the company's experimental obesity drug [1]. The court's answer will determine which type of marketing application Lilly may file and whether a future approval carries twelve years of market exclusivity or five [1].
The dispute is about legal categories rather than clinical results. Lilly has said it wants to submit a Biologics License Application instead of a New Drug Application [1]. Biologics receive twelve years of protection from competing versions; new drugs receive five [1]. The FDA decided that retatrutide is neither a protein nor a biological product [1]. A district court set that determination aside but returned the larger question to the agency, which prompted the appeal [1]. Lilly's second-quarter results describe the classification as still tied up in litigation [1]. When the appeals court will rule has not been reported.
The clinical news has moved on a separate track. On August 5, 2026, Lilly said the retatrutide data package was complete, following positive topline results from two Phase 3 trials announced July 23 [1]. In TRIUMPH-3, adults with severe obesity and established cardiovascular disease lost up to 22.6% of their body weight by week 80. Participants with type 2 diabetes in TRIUMPH-2 lost up to 20.8% over the same 80 weeks [1]. Lilly says those results support registration in obesity, obstructive sleep apnoea and knee osteoarthritis pain [1]. The company's stated target for submitting retatrutide to the FDA is the first quarter of 2027 [1].
Retatrutide remains investigational, and Lilly has filed six US lawsuits against sellers of the unapproved drug [1].
Why it matters for patients
Whichever way the Seventh Circuit rules, retatrutide cannot be prescribed in the United States today [1]. The hearing does not decide whether regulators approve the drug. It decides the pathway any approval would travel and how long that approval would be shielded from copies, a gap of seven years between the two options [1].
Timing is a separate question. Lilly's filing target of the first quarter of 2027 is the only date the company has given for the US submission [1]. Whether the appeal would change that schedule has not been reported. Because the drug is still under study, products sold outside authorized channels are unapproved, which is the basis for the lawsuits Lilly has brought against six US sellers [1].
For people already using approved GLP-1 medicines such as semaglutide or tirzepatide, the case has no effect on their prescriptions. It concerns a drug that is not yet on the market.
What happens next
- September 24, 2026: the Seventh Circuit hears oral arguments in Lilly's appeal against the FDA [1].
- First quarter of 2027: Lilly's target date for filing retatrutide with the FDA [1].
- Before the end of 2026: further results from the TRIUMPH program are expected [1].
- Late 2026: a separate FDA decision is expected on CagriSema, a Novo Nordisk combination product unrelated to retatrutide [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.